On-Demand 

The development of cost-effective and safe total synthetic routes for active pharmaceutical ingredients (APIs) is a painstaking and complex process. This critical early development stage significantly impacts overall manufacturing costs, dictates the required purification and isolation technologies along with inherent solvent usage, and consequently contributes to key environmental hotspots in pharmaceutical manufacturing. Traditional route design methods, which rely heavily on human expertise and labour-intensive trial-and-error approaches, can result in suboptimal and costly pathways.

This webcast will showcase how emerging AI-powered and computer-assisted retrosynthesis (CAR) technologies are revolutionizing route design, enabling more efficient early-stage decision-making in pharma. These innovations lay the foundation for safer, more sustainable, and green-by-design pharmaceuticals.

Through experimentally validated examples, the webcast will demonstrate how CAR, combined with green-by-design strategies, can reduce costs, enhance productivity, and improve environmental performance while minimizing impurities and side products. Moreover, the webcast will explore optimal new design strategies for shared reaction routes across multiple APIs, leveraging the synergistic combination of multi-target CAR and flow chemistry.

Learning Objectives:

1. Current challenges and emerging opportunities for computer assisted and AI-powered retrosynthesis
2. How we can benchmark the current tools and methods for computer assisted retrosynthesis
3. How computer-assisted retrosynthesis contributes to safe and green-by-design pharmaceuticals